CSI Market
Sign In | Register

Ambrx Biopharma Inc (AMAM) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access AMAM Annual Cash Flow →
Tracking cash flow results across Ambrx Biopharma Inc to Sep 30 2022 helps illustrate how Sep 30 2023's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2023)
9 Months 		(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Operating Activities
Income-56.12
Depreciation & amortization0.64
Amortization of Other Assets0.47
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation9.64
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Impairment Of Intangible Assets Excluding Goodwill-
Redeemable Non Controlling Interest Change In Fair Value2.05
Non Cash Lease Expense0.53
Increase Decrease In Operating Lease Liability-0.33
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.25
Increase (Decrease) in Accounts Payable2.42
Increase (Decrease) in Accrued Liabilities0.42
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.87
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-44.99
Investing Activities
Capital Expenditures-1.08
Sale of Capital Items0.00
Short-term Investments Proceeds86.63
Payments to Acquire Available-for-sale Securities, Debt-40.65
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities44.90
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock18.07
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Payroll Protection Program Loan-
Repayment From Payroll Protection Program Loan-0.93
Proceeds From Directors And Officers Insurance Premium Financing Agreement77.78
Payments Of Directors And Officers Insurance Premium Financing Agreement74.66
Payments Of Common Stock Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities169.58
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-46.08
Total Cash Flow169.49
4 historic quarters locked

Sign in to unlock the full Ambrx Biopharma Inc cash flow history.

Sign In Create Free Account

About Ambrx Biopharma Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-23-062916

Figures are derived from filed reports and may be restated. Historical data is subject to revision.